Axsome Therapeutics, Inc.
NASDAQ:AXSM · NASDAQ Global Market
+$0.25 today
Vol 0.71M · Avg 0.72M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-207.5%
avg -508.8%
ROIC
-44.0%
avg -106.1%
ROA
-26.6%
avg -71.6%
Analysis
ROA is currently the strongest return metric at -26.6% versus its period average of -71.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Herriot Tabuteau | Founder, Chairman, Chief Executive Officer & President | $1.92M | — | 58 | $99,330.00 | 0.19% |
Mark L. Jacobson | Chief Operating Officer | $1.06M | — | 43 | $30,389.00 | 0.06% |
Nick Pizzie | Chief Financial Officer | $974,594.00 | — | 51 | $75,867.00 | 0.15% |
Hunter Murdock | General Counsel & Secretary | $960,636.00 | — | 46 | $7,224.00 | 0.01% |
Ari Maizel | Chief Commercial Officer | $924,989.00 | — | 47 | $23,710.00 | 0.05% |
Darren Opland | Director of Corporate Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$200,466.30
Sells
45
$143.04M
Net Sentiment
$142.84M
Net selling
Most Active
TABUTEAU HERRIOT
17 transactions
1–10 of 48
Analysis
Insiders reported 3 buys worth $200,466.30 and 45 sells worth $143.04M over the last 12 months. That adds up to net selling of $142.84M. TABUTEAU HERRIOT was the most active insider with 17 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A14 analysts |
| Revenue | N/A | N/A | N/A | N/A8 analysts |
| Net Income | N/A | N/A | N/A | N/A8 analysts |
| EBIT | N/A | N/A | N/A | N/A8 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.26B
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$11.42B
Cytokinetics, Incorporated
NASDAQ:CYTK
$9.72B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Metsera, Inc.
MTSR
$7.43B
Vaxcyte, Inc.
NASDAQ:PCVX
$7.32B
Merus N.V.
MRUS
$6.83B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.57B
Abivax S.A.
NASDAQ:ABVX
$6.57B
CRISPR Therapeutics AG
NASDAQ:CRSP
$5.12B
Who manages AXSM?
Axsome Therapeutics, Inc. (AXSM) lists 6 active executives. The top listed executive is Ari Maizel, Chief Commercial Officer.
Are AXSM insiders buying or selling?
Recent insider activity shows net selling of $229.94M.
Explore More
Continue the stock analysis
Jump to another research area for this company.